On April 23, 2018 Verastem, Inc. (NASDAQ: VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, reported that it will host an Analyst and Investor Day titled, "Duvelisib: Harnessing the Power of Dual PI3K Inhibition," on Wednesday, May 2, 2018 from 10:30 am – 1:00 pm ET in New York City (Press release, Verastem, APR 23, 2018, View Source;p=RssLanding&cat=news&id=2343842 [SID1234525595]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The agenda will include an in-depth discussion of the Company’s lead oral oncology candidate, duvelisib, including the unmet need of patients, where phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma inhibitors fit into the treatment paradigm and the opportunity for duvelisib in the growing chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) population and beyond.
The program will also feature key opinion leaders in the hematologic oncology field, including:
Jennifer Brown, MD, PhD
Associate Professor of Medicine, Harvard Medical School Director, and Director, CLL Center of the Division of Hematologic Malignancies, Dana-Farber Cancer Institute
Ian Flinn, MD, PhD
Director, Blood Cancer Research Program at Sarah Cannon Research Institute, and Lead Investigator of the DUO and DYNAMO Studies
Steven Horwitz, MD
Medical Oncologist, Memorial Sloan Kettering Cancer Center and NYC Health + Hospitals/Bellevue
Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd
Physician, Medical Director of the Chronic Lymphocytic Leukemia (CLL) Society and CLL Patient
Lori Kunkel, MD
Oncology Drug Development Expert and Biotech Advisor, Member of the Board of Directors at Tocagen Inc., Former Chief Medical Officer, Pharmacyclics
Kindly reach out to Marianne Lambertson at [email protected] for any inquiries.
A live and archived webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at www.verastem.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.